Penumbra Inc. announced that the company’s ACE64 aspiration thrombectomy system received 510(k) marketing clearance from the U.S. Food and Drug Administration for the revascularization of large vessel occlusions in patients with acute ischemic stroke.

REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom sirolimus-eluting bioresorbable scaffold in March. The scaffold, made from REVA's advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time.

Health and Human Services Secretary Sylvia M. Burwell announced an opportunity for healthcare providers to decrease cardiovascular disease risk for Medicare beneficiaries through a new payment model. Using the model, providers can assess an individual patient’s risks for heart attack or stroke and work with them to reduce those risks. Secretary Burwell made the announcement at the White House Conference on Aging regional forum in Boston.

Medtronic announced the launch of the Euphora semicompliant balloon dilatation catheter in countries that recognize the CE (Conformité Européene) mark in February. The first patient case with the Euphora was performed in the same month by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom.

Researchers from the University of Chicago and Stanford University combed through scientific literature on the pharmacogenomics of 71 leading cardiovascular drugs to help physicians better understand how genetic variations can affect patient response. The researchers compiled summaries of the information, published in the June issue of the Mayo Clinic Proceedings, to help physicians make better-informed clinical decisions about these drugs.

Beaumont Hospital, Royal Oak is one of the first centers in the United States to use a new minimally invasive heart pump designed to provide temporary support for patients with severe right-side heart failure.

Bracco, Lumason, first U.S. echocardiography procedure, Morristown

Bracco Imaging announced that the first echocardiography imaging procedure with Lumason was performed in May at Morristown Medical Center, part of the Atlantic Health System, in New Jersey. This is the first administration after the development of the agent (sulfur hexafluoride lipid-type A microspheres) in the United States and approval by the U.S. Food and Drug Administration. The announcement was made through Bracco Imaging’s affiliate Bracco Diagnostics Inc.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now